We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Role of CCL2 in Alcoholic Liver Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01128010
Recruitment Status : Completed
First Posted : May 21, 2010
Last Update Posted : May 21, 2010
Information provided by:
Erasme University Hospital

Brief Summary:
Immune dysregulations, including cytokines and chemokines secretions occurs in alcoholic liver disease. Serum levels and liver expression of CCL2 are increased in patients with alcoholic hepatitis but the role of this chemokine in the pathogenesis of alcoholic liver disease is nevertheless unknown. The aim of the study is to analyze plasma level and liver expression of CCL2 and their relation with liver disease severity and inflammatory infiltrate in our cohort of alcoholic patients. We studied also the association between -2518 CCL2 polymorphism and the severity of alcoholic liver disease.

Condition or disease
Alcoholic Liver Disease

Study Type : Observational
Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Diseases
U.S. FDA Resources

alcoholic liver disease
alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Consecutive patients undergoing transjugular liver biopsy for alcoholic liver disease will be include in the study to measure plasma levels and hepatic expression of CCL2. We determine also the rs1024611 polymorphism of these patients. All these parameters are correlated to severity of the disease.

The frequency of the presence of this polymorphism was also compared to a population of healthy subjects.


ALD patients

Inclusion Criteria:

  • Excess alcohol intake
  • Abnormality of liver biopsy compatible with alcoholic aetiology
  • Caucasian ethnicity

Exclusion Criteria:

  • Presence of any other chronic liver disease
  • co-infection with HIV Controls Inclusion criteria
  • Caucasian ethnicity
  • presence of a disease

ClinicalTrials.gov Identifier: NCT01128010     History of Changes
Other Study ID Numbers: DD-CCL2
First Posted: May 21, 2010    Key Record Dates
Last Update Posted: May 21, 2010
Last Verified: December 2002

Additional relevant MeSH terms:
Liver Diseases
Liver Diseases, Alcoholic
Digestive System Diseases
Alcohol-Induced Disorders
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders